Skip to content
Megan A. Baumgart, M.D.

Megan A. Baumgart, M.D.

Cancer

UR Medicine Faculty The University of Rochester Medical Faculty Group (URMFG) consists of over 900 specialist and primary care providers spanning 19 departments. URMFG is certified by the National Committee for Quality Assurance.
Accountable Health Partner Accountable Health Partners (AHP) is a network of over 2,000 community and UR medical faculty and a dozen leading hospitals throughout the region. AHP offers a full range of care.
Accepting New Patients

Contact

About Me

I chose the field of oncology because I want to help patients through one of the most difficult experiences a person can have.

Cancer treatment requires a team approach involving the patient, medical oncologist, nurses and support staff, as well as other medical teams such as radiation oncolo...
I chose the field of oncology because I want to help patients through one of the most difficult experiences a person can have.

Cancer treatment requires a team approach involving the patient, medical oncologist, nurses and support staff, as well as other medical teams such as radiation oncology and surgery who are often part of a patient's care. I work with patients to help them understand the overall treatment plan – especially the role of chemotherapy in the treatment of their disease – and support them throughout the course of treatment.

I am optimistic about the future of cancer treatment and want to work towards finding new and better treatment strategies for lung and head and neck cancers through the development of our clinical trials program. We currently have several clinical trials evaluating the role of immunotherapy for the treatment of metastatic head and neck cancers open for enrollment, as well as other clinical trials focused on answering important questions regarding the management of these diseases.

Conditions I Treat

- Small cell lung cancer
- Non-small cell lung cancer
- Head and neck cancers
- Thyroid cancer

Certified Specialties

Internal Medicine - American Board of Internal Medicine

Medical Oncology - American Board of Internal Medicine

Faculty Appointments

Associate Professor - Department of Medicine, Hematology/Oncology (SMD)

Credentials

Residency & Fellowship

Fellowship, Medical Oncology, Yale New Haven Hospital. 2011 - 2014

Residency, Internal Medicine, Rhode Island Hospital GME. 2008 - 2010

Internship, Internal Medicine, Rhode Island Hospital GME. 2007 - 2008

Education

MD | Albany Medical College. 2007

Awards

Early Career Women Faculty Leadership Development Seminar. 2019

Annual Award for Outstanding Oncology Research. 2014

Albany Medical College- Distinction in Biomedical Ethics. 2007

Research

Clinical Trials

A pilot study of pembrolizumab and single agent chemotherapy as first line treatment for patients with locally advanced or metastatic non-small cell lung cancer with Eastern Cooperative Oncology Group (ECOG) performance status of 2

Lead Researcher: Megan A Baumgart

The purpose of this study is to understand if treatment with one chemotherapy medication combined with immune therapy (pembrolizumab) is tolerable and effective for patients with lung cancer and performance status of 2 (PS2), which means you have lim...

A Phase II Study of AMG 510 in Participants With Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)

Lead Researcher: Megan A Baumgart

This phase II Lung-MAP treatment trial studies the effect of AMG 510 in treating non-squamous non-small cell lung cancer that is stage IV or has come back (recurrent) and has a specific mutation in the KRAS gene, known as KRAS G12C. Mutations in this...

Nivolumab Versus Observation in Treating Patients With Locally Advanced, Intermediate Risk HPV-Positive Oropharyngeal Cancer (EA3161)

Lead Researcher: Megan A Baumgart

This phase III trials studies whether maintenance immunotherapy (nivolumab) following definitive treatment with radiation and chemotherapy (cisplatin) result in significant improvement in overall survival (time being alive) and progression-free survi...

LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)

Lead Researcher: Megan A Baumgart

This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP...

Publications

Journal Articles

PUB031 PRIMAL: A Phase 1b Study of PEGPH20 plus Docetaxel in Patients with Previously Treated Hyaluronan (HA)-High Advanced NSCLC

Baumgart, M.; Bazhenova, L.; Haggstrom, D.; Baranda, J.; Belani, C.

Journal of Thoracic Oncology. 2017; 12(1): S1465.

Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel in patients with advanced solid tumors.

Abu-Khalaf MM, Baumgart MA, Gettinger SN, Doddamane I, Tuck DP, Hou S, Chen N, Sullivan C, Lezon-Geyda K, Zelterman D, Hatzis C, Deshpande H, Digiovanna MP, Azodi M, Schwartz PE, Harris LN

Cancer.. 2015 June 1121 (11):1817-26. Epub 02/03/2015.

New molecular targets on the horizon in non-small cell lung cancer

Baumgart, M.

American Journal of Hematology and Oncology. 2015; 11(6): 10-13.

Ratings & Reviews

At URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information. Learn more about our survey process.